Appili Therapeutics, Inc. operates as a biopharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. It focuses on building and advancing a diverse portfolio of anti-infective programs such as ATI-1501, ATI-1503, and ATI-1701. The company was founded on May 7, 2015 and is headquartered in Halifax, Canada.
—
Appili Therapeutics, Inc. operates as a biopharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. It focuses on building and advancing a diverse portfolio of anti-infective programs such as ATI-1501, ATI-1503, and ATI-1701. The company was founded on May 7, 2015 and is headquartered in Halifax, Canada.
—
Daily adjusted close
Appili Therapeutics, Inc. operates as a biopharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. It focuses on building and advancing a diverse portfolio of anti-infective programs such as ATI-1501, ATI-1503, and ATI-1701. The company was founded on May 7, 2015 and is headquartered in Halifax, Canada.